There are no generally accepted regimens for the treatment of H. pylori infection in patients with gastritis or duodenal ulcers. However, metronidazole based regimens have been reported to be among the most successful. Resistance to metronidazole, clarithromycin, and amoxicillin was determined for 46 clinical isolates of Helicobacter pylori in Saudi Arabia and tested by E test. Of these isolates, 69.5% was resistant to metronidazole (MIC > 8 mg/l), 21% to clarithromycin (MIC > 1 mg/l) and 11% were multiresistant. No resistance to amoxicillin was observed. Resistance to metronidazole was more common in isolates from females than in those form males. In conclusion, the present study demonstrates high metronidazole resistance rate of H. pylori isolates in Saudi Arabia. Regimens containing metronidazole are best avoided. Trials to test other antimicrobial combinations are recommended.
INTRODUCTION
Helicobacter pylori (H. pylori) causes gastritis and ulcer disease and is considered as a risk factor for the development of mucosa-associated lymphoma and gastric cancer (12). Most consensus guidelines now are recommending for the eradication of H. pylori infected patients. The most commonly using treatments are triple therapies consisting of a proton pump inhibitor, clarithromycin and metronidazole or amoxicillin (11). The primary and secondary resistance rates reported worldwide vary from 1 to 58% for clarithromycin and from 5 to 76% for metronidazole (6,17).
Resistance to one or both of these antibiotics significantly reduces treatment success (19) .
The clinical importance of this resistance makes it necessary for antibiotic treatment decisions to be based on valid and reproducible in vitro susceptibility testing results.
Reported discrepant susceptibility test results are due to variations in the methods and conditions used for susceptibility testing (18, 20) . The National Committee for Clinical Laboratory Standards (NCCLS) has recently published guidelines for in vitro susceptibility testing of H. pylori using an agar dilution method (26 
MATERIALS AND METHODS

Clinical specimens
Forty-six gastric biopsies of patients with gastritis or duodenal ulcer were underwent endoscopically at Al-Iman General Hospital, Riyadh, Saudi Arabia. Three gastric biopsy specimens were obtained from each patient; one was used for rapid CLO test (Campylobacter like organism for determination of urease activity) (Oxoid, Basingstoke, UK) and the remaining two were placed in the sterile screwcapped tubes containing 0.5 ml Brucella broth media (Oxoid) and transported for isolation and antibiotic susceptibility test. The biopsy specimens were ground in a tissue grinder.
Using a pasture pipette, about two drops of homogenates were inoculated into H. pylori selective agar (Oxoid) and streaked with a bacteriological loop. The inoculated culture media were transferred into microaerophilic condition (jars with CampyGen, Oxoid) at 37℃ for 7 days.
Bacterial strains
Forty-six clinical strains of H. pylori isolated from patients with gastritis or duodenal ulcer were tested. The strains were identified by Gram staining and oxidase, catalase, and urease reactions. After identification, the bacteria were suspended in the Eppendorf tubes containing Brucella broth media with 30% glycerol and stored at -70℃ until use.
Control strains
H. pylori ATCC 43504 was the reference strain used for quality control and was purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA).
Antimicrobial agents
The antimicrobial agents tested against H. pylori included metronidazole, clarithromycin, and amoxicillin. The E test strips of each antibiotic were purchased from AB Biodisk (Solna, Dalvagen, Sweden).
Antimicrobial susceptibility testing
Thawed isolates were inoculated onto Mueller-Hinton agar supplemented with 5% sheep blood and were incubated under a microaerophilic atmosphere (CampyGen, Basingstoke, UK) for 72 h at 37℃. Colonies were suspended in 2 ml of Dulbecco's modified Eagle medium (ICN Biomedicals, Livermore, CA, USA) to achieve a turbidity equivalent to that of the no. 3 McFarland opacity standard.
E test
Plates containing Mueller-Hinton agar supplemented with 5% heparinized horse blood were used for the E test. All antimicrobial agents except metronidazole were tested at concentrations ranging from 0.016 to 128 mg/l; Clarithromycin and amoxicillin were tested at 0.016 to 8 mg/l. The agar plates were inoculated by confluent swabbing of the surface with the adjusted inoculum suspensions. After the surface of the inoculated plates had dried at 37℃ inside a microaerophilic chamber, E test strips were applied onto the surface of each agar plate. The plates were incubated at 37℃ under microaerophilic conditions (CampyGen). MICs were read after 72 h of incubation on the basis of the intersection of the elliptical zone of growth inhibition with the MIC scale on the E test strip. Strains were considered as resistant when the MIC was > 8 mg/l for metronidazole, > 1 mg/l for clarithromycin and > 0.5 mg/l for amoxicillin.
These breakpoints were used based on the recommendations from the National Committee for Clinical Laboratory Standards (NCCLS) (25, 29) .
RESULTS
The antimicrobial susceptibility test results of all H. pylori strains are presented in Table 1 In contrast, resistance rates were higher in female patients (n=24) for metronidazole (70.8%, n=17) and for clarithromycin (25%, n=6).
For patients aged < 40 years (n=14), 57.1% of isolates (n=8) was metronidazole-resistant and 28.5% (n=4) clarithromycin-resistant. In the >=40 years age group (n=32), resistance rates were higher for metronidazole (75%, n=24) and to a lesser extent for clarithromycin (18.8%, n=6), compared with the younger adult age group. Clarithromycin resistance rates were higher in female than male patients in both the < 40 age group (33.3% vs 25%) and in the >=40 years age group (22.2% vs 14%). In contrast, it was only in the >=40 years group that metronidazole resistance was higher in females (78% vs 71%) ( Table 2 ).
The proportion of female patients in the >= 40 group (n=18) infected with metronidazole-resistant H. pylori was higher (78%) than in females < 40 years (50%, n=6) ( Table   2 ). There was no difference in clarithromycin resistance rates in females from either age group (Table 2) . Similarly, antibiotic resistance rates did not differ significantly between age groups for male patients (Table 2) .
DISCUSSION
The efficacy of the treatment of gastric infection caused by H. pylori could be reduced by the occurrence of primary or acquired resistance to various drugs, especially to metronidazole (4). This had made the susceptibility testing of H. pylori increasingly important for the search for efficient antimicrobial combinations that allow for the eradication of this bacterium from the stomach. Many studies had used an agar dilution method (5,16), but it is difficult to perform this routinely and impractical for clinical use when testing individual isolates. The E test is now widely accepted as an alternative, providing results comparable with those of agar dilution (8,27). Moreover, E test is very easy to perform and not labor intensive (2). In this study this point was addressed by using a control strain (ATCC 43504) with (21) 0.032 2 ( 4) 10 (21) 13 (28) 0.064 2 ( 4) 4 ( 8) 17 (37) 0.125 1 ( 2) 3 ( 7) 3 ( 7) 0.25 1 ( 2) 6 (13) 3 ( 7) 0.5 1 ( 2) 3 ( 7) 0 1 0 3 ( 7) 0 2 3 ( 7) 10 (21) 22) . In the present study the incidence of metronidazole resistance was 69.5%, a high percentage when compared to the developed countries (13).
It has been documented that metronidazole resistance is higher in female patients (7,31) This is most likely to be due to the use of metronidazole to treat gynaecological infections. Interestingly, the clarithromycin resistance rate was higher in female compared with male patients in both age groups. Higher clarithromycin resistance rate in females was documented in a multi-centre study in the United States 
